-
公开(公告)号:US08168794B2
公开(公告)日:2012-05-01
申请号:US12380458
申请日:2009-02-26
IPC分类号: A61K31/4545 , C07D213/75 , C07D417/12 , C07D413/14
CPC分类号: C07D417/14 , A61K31/4439 , A61K31/4545 , C07D417/12
摘要: The present invention relates to new compounds of Formulas I and II, their tautomers, stereoisomers and polymorphs, and pharmaceutically acceptable salts, esters, metabolites or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the inhibition of Pim kinase activity and/or the prophylaxis or treatment of cancer.
摘要翻译: 本发明涉及式I和II的新化合物,其互变异构体,立体异构体和多晶型物及其药学上可接受的盐,酯,代谢物或前药,新化合物与药学上可接受的载体的组合物,以及新化合物的用途, 单独或与至少一种另外的治疗剂组合,抑制Pim激酶活性和/或预防或治疗癌症。
-
公开(公告)号:US20050153905A1
公开(公告)日:2005-07-14
申请号:US10831522
申请日:2004-04-23
申请人: Matthew Burger , Daniel Chu
发明人: Matthew Burger , Daniel Chu
IPC分类号: A61K31/7052 , A61P31/04 , C07H17/08
CPC分类号: C07H17/08
摘要: Antimicrobial ketolide compounds are provided having the formula (A): as well as pharmaceutically acceptable salts, esters or prodrugs thereof, pharmaceutical compositions comprising such compounds, methods of treating bacterial infections by the administration of such compounds, and processes for the preparation of the compounds.
摘要翻译: 提供具有式(A)的抗微生物酮内酯化合物:以及其药学上可接受的盐,酯或前药,包含这些化合物的药物组合物,通过施用这些化合物治疗细菌感染的方法,以及制备化合物的方法 。
-
公开(公告)号:US20140249135A1
公开(公告)日:2014-09-04
申请号:US14273595
申请日:2014-05-09
申请人: Matthew Burger , Mika Lindvall , Wooseok Han , Jiong Lan , Gisele Nishiguchi , Cynthia Shafer , Cornelia Bellamacina , Kay Huh , Gordana Atallah , Christopher McBride , William Antonios-McCrea, JR. , Tatiana Zavorotinskaya , Annette Walter , Pablo Dominguez Garcia
发明人: Matthew Burger , Mika Lindvall , Wooseok Han , Jiong Lan , Gisele Nishiguchi , Cynthia Shafer , Cornelia Bellamacina , Kay Huh , Gordana Atallah , Christopher McBride , William Antonios-McCrea, JR. , Tatiana Zavorotinskaya , Annette Walter , Pablo Dominguez Garcia
IPC分类号: C07D401/12 , A61K31/55 , A61K31/497 , A61K31/4545 , A61K31/444 , C07D491/113 , C07D403/12 , A61K31/506 , C07D241/28 , C07D401/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D497/04 , C07D403/14 , A61K31/553
CPC分类号: C07D401/12 , A61K31/444 , A61K31/4545 , A61K31/497 , A61K31/506 , A61K31/55 , A61K31/553 , C07D241/24 , C07D241/28 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D491/113 , C07D497/04
摘要: New compounds, compositions and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
摘要翻译: 提供了在人或动物受试者中抑制与肿瘤发生相关的激酶活性的新化合物,组合物和方法。 在某些实施方案中,化合物和组合物有效抑制至少一种丝氨酸/苏氨酸激酶或受体酪氨酸激酶的活性。 新化合物和组合物可以单独使用或与至少一种另外的药剂组合使用,用于治疗丝氨酸/苏氨酸激酶或受体酪氨酸激酶介导的病症,例如癌症。
-
公开(公告)号:US20050065169A1
公开(公告)日:2005-03-24
申请号:US10850429
申请日:2004-05-21
申请人: Weibo Wang , Liana Lagniton , Ryan Constantine , Matthew Burger
发明人: Weibo Wang , Liana Lagniton , Ryan Constantine , Matthew Burger
IPC分类号: A61K31/519 , A61P35/00 , C07D487/02 , C07D495/04
CPC分类号: C07D239/88 , C07D495/04 , Y10S435/81
摘要: Heteroaryl-fused pyrimidinyl compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the heteroaryl-fused pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the heteroaryl-fused pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.
摘要翻译: 杂芳基稠合的嘧啶基化合物,其药学上可接受的盐和前药; 包括药学上可接受的载体和一种或多种杂芳基稠合的嘧啶基化合物的组合物,单独或与至少一种另外的治疗剂组合。 将杂芳基稠合的嘧啶基化合物单独使用或与至少一种另外的治疗剂组合使用在预防或治疗增殖性疾病中的方法。
-
公开(公告)号:US20120208815A1
公开(公告)日:2012-08-16
申请号:US12449701
申请日:2008-03-03
申请人: Matthew Burger , Mika Lindvall , Wooseok Han , Jiong Lan , Gisele Nishiguchi , Cynthia Shafer , Comelia Bellamacina , Kay Huh , Gordana Atallah , Christopher Mcbride , William Antonios-Mccrea, JR. , Tatiana Zavorotinskaya , Annette Walter , Pablo Garcia
发明人: Matthew Burger , Mika Lindvall , Wooseok Han , Jiong Lan , Gisele Nishiguchi , Cynthia Shafer , Comelia Bellamacina , Kay Huh , Gordana Atallah , Christopher Mcbride , William Antonios-Mccrea, JR. , Tatiana Zavorotinskaya , Annette Walter , Pablo Garcia
IPC分类号: A61K31/5377 , A61K31/4545 , A61P35/00 , C07D413/14 , A61K31/496 , C07D417/14 , A61K31/506 , A61K31/497 , C07D401/14 , C12N5/071
CPC分类号: C07D401/12 , C07D213/78 , C07D239/28
摘要: New compounds, compositions and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
摘要翻译: 提供了在人或动物受试者中抑制与肿瘤发生相关的激酶活性的新化合物,组合物和方法。 在某些实施方案中,化合物和组合物有效抑制至少一种丝氨酸/苏氨酸激酶或受体酪氨酸激酶的活性。 新化合物和组合物可以单独使用或与至少一种另外的药剂组合使用,用于治疗丝氨酸/苏氨酸激酶或受体酪氨酸激酶介导的病症,例如癌症。
-
公开(公告)号:US20110195980A1
公开(公告)日:2011-08-11
申请号:US13060971
申请日:2009-08-31
申请人: Matthew Burger , Mika Lindvall
发明人: Matthew Burger , Mika Lindvall
IPC分类号: A61K31/506 , C12N9/99 , C07D417/14 , A61K31/4709 , C07D401/14 , A61K31/4375 , C07D471/02 , A61P43/00
CPC分类号: C07D471/04 , C07D401/04 , C07D401/14 , C07D403/14 , C07D417/14
摘要: New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
摘要翻译: 提供了新的化合物,组合物和方法抑制Provirus与人或动物受试者中与肿瘤发生相关的Maloney激酶(PIM激酶)活性的整合。 在某些实施方案中,化合物和组合物有效抑制至少一种PIM激酶的活性。 新化合物和组合物可以单独使用或与至少一种另外的药剂组合使用,用于治疗丝氨酸/苏氨酸激酶或受体酪氨酸激酶介导的病症,例如癌症。
-
公开(公告)号:US07163924B2
公开(公告)日:2007-01-16
申请号:US10831522
申请日:2004-04-23
申请人: Matthew Burger , Daniel Chu
发明人: Matthew Burger , Daniel Chu
CPC分类号: C07H17/08
摘要: Antimicrobial ketolide compounds are provided having the formula (A): as well as pharmaceutically acceptable salts, esters or prodrugs thereof, pharmaceutical compositions comprising such compounds, methods of treating bacterial infections by the administration of such compounds, and processes for the preparation of the compounds.
摘要翻译: 提供具有式(A)的抗微生物酮内酯化合物:以及其药学上可接受的盐,酯或前药,包含这些化合物的药物组合物,通过施用这些化合物治疗细菌感染的方法,以及制备化合物的方法 。
-
公开(公告)号:US08829193B2
公开(公告)日:2014-09-09
申请号:US13447988
申请日:2012-04-16
IPC分类号: C07D417/14 , A61K31/4545 , A61K31/4439 , C07D417/12
CPC分类号: C07D417/14 , A61K31/4439 , A61K31/4545 , C07D417/12
摘要: The present invention relates to new compounds of Formulas I and II, their tautomers, stereoisomers and polymorphs, and pharmaceutically acceptable salts, esters, metabolites or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the inhibition of Pim kinase activity and/or the prophylaxis or treatment of cancer.
摘要翻译: 本发明涉及式I和II的新化合物,其互变异构体,立体异构体和多晶型物及其药学上可接受的盐,酯,代谢物或前药,新化合物与药学上可接受的载体的组合物,以及新化合物的用途, 单独或与至少一种另外的治疗剂组合,抑制Pim激酶活性和/或预防或治疗癌症。
-
公开(公告)号:US20140228363A1
公开(公告)日:2014-08-14
申请号:US14258764
申请日:2014-04-22
申请人: Matthew Burger , Yu Ding , Wooseok Han , Gisele Nishiguchi , Alice Rico , Robert Lowell Simons , Aaron R. Smith , Victoriano Tamez, JR. , Huw Tanner , Lifeng Wan
发明人: Matthew Burger , Yu Ding , Wooseok Han , Gisele Nishiguchi , Alice Rico , Robert Lowell Simons , Aaron R. Smith , Victoriano Tamez, JR. , Huw Tanner , Lifeng Wan
IPC分类号: C07D401/12 , A61K45/06 , A61K31/506 , C07D417/12 , A61K31/4439 , C07D409/14 , C07D417/14 , C07D405/14 , C07D401/14 , A61K31/5377 , C07D413/14 , A61K31/444 , A61K31/497
CPC分类号: A61K31/4439 , A61K31/444 , A61K31/4745 , A61K31/497 , A61K31/506 , A61K31/513 , A61K31/519 , A61K31/5377 , A61K31/664 , A61K31/704 , A61K31/7068 , A61K33/24 , A61K39/395 , A61K45/06 , C07D213/81 , C07D401/12 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/12 , C07D417/14 , A61K2300/00
摘要: The present invention provides a compound of formula (I): as further described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.
摘要翻译: 本发明提供式(I)化合物:如本文进一步描述的,及其药学上可接受的盐,对映异构体,旋转异构体,互变异构体或外消旋体。 还提供了使用式I化合物治疗PIM激酶介导的疾病或病症的方法和包含这些化合物的药物组合物。
-
公开(公告)号:US20110195956A1
公开(公告)日:2011-08-11
申请号:US13061009
申请日:2009-08-31
申请人: Matthew Burger , Jiong Lan
发明人: Matthew Burger , Jiong Lan
IPC分类号: A61K31/55 , C12N9/99 , C07D401/12 , A61K31/517 , C07D401/14 , C07D417/14 , A61P35/00
CPC分类号: C07D401/12
摘要: New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
摘要翻译: 提供了新的化合物,组合物和方法抑制Provirus与人或动物受试者中与肿瘤发生相关的Maloney激酶(PIM激酶)活性的整合。 在某些实施方案中,化合物和组合物有效抑制至少一种PIM激酶的活性。 新化合物和组合物可以单独使用或与至少一种另外的药剂组合使用,用于治疗丝氨酸/苏氨酸激酶或受体酪氨酸激酶介导的病症,例如癌症。
-
-
-
-
-
-
-
-
-